Arcutis Biotherapeutics vs Evolus
ARQT and EOLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and EOLS compare
Arcutis Biotherapeutics is the larger company, worth 7.3 times as much as Evolus ($3.6B against $490M).
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus 13.9% for Evolus).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 5.9% compared with −9.6% at Evolus.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 7 for Evolus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | EOLS |
|---|---|---|
| Size and price | ||
| Market cap | $3.6B | $490M |
| Share price | $28.38 | $7.42 |
| Change, 1 year | 19.5% | 5.2% |
| Change, 5 years | 56.0% | 16.3% |
| Beta (5Y) | 0.92 | 1.14 |
| Employees | 354 | 334 |
| StockData Score | ||
| Total score | 11 (better) | 7 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 129× | – |
| P/S | 7.0× | 1.5× (better) |
| P/B | 14.6× | – |
| EV/EBITDA | 97.2× | – |
| P/FCF | 59.7× | – |
| FCF yield | 1.7% (better) | −1.0% |
| Fair value | $6.03 | – |
| Margin of safety | −371% | – |
| Growth | ||
| Revenue growth (TTM) | 60.0% (better) | 13.9% |
| Revenue growth, 5Y average | – | 39.4% |
| Profitability | ||
| Gross margin | 91.2% (better) | 66.4% |
| Operating margin | 6.9% (better) | −4.8% |
| Net margin | 5.9% (better) | −9.6% |
| FCF margin | 11.7% (better) | −1.5% |
| Return on equity | 14.9% | – |
| Return on invested capital | 32.9% (better) | −16.3% |
| Financial health | ||
| Debt / equity | 0.45 | – |
| Net debt / EBITDA | −4.27 | – |
| Interest coverage | 2.6× (better) | −1.0× |
| Current ratio | 2.92 (better) | 1.42 |
| Altman Z-score | 6.58 (better) | −1.28 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 84.0% |
| Held by insiders | 9.3% | 4.1% |
| Insider net buying, 12 months | −$11.1M | −$1.8M (better) |
| Short interest, % of float | 15.9% | 9.5% |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- EOLS stock overview
- EOLS income statement
- EOLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.